Glaucatotones A-I: Guaiane-type sesquiterpenoids from the roots of Lindera glauca with anti-inflammatory activity.

Anti-inflammatory Cytotoxicity Lindera glauca Norsesquiterpenoids Sesquiterpenoids

Journal

Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703

Informations de publication

Date de publication:
17 Jan 2024
Historique:
received: 24 10 2023
revised: 10 01 2024
accepted: 12 01 2024
medline: 29 1 2024
pubmed: 29 1 2024
entrez: 28 1 2024
Statut: aheadofprint

Résumé

Glaucatotones A - I, nine new guaiane-type sesquiterpenoids, along with two reported compounds, namely (1β,5β)-1-hydroxyguaia-4(15),11(13)-dieno-12,5-lactone (10) and pseudoguaianelactone C (11), were isolated from the roots of Lindera glauca. The structures and absolute configurations of these compounds were elucidated by extensive spectroscopic analyses, single-crystal X-ray diffraction, and comparison of experimental and calculated electronic circular dichroism (ECD) data. Structurally, glaucatotone A (1) is characterized as a dihomosesquiterpenoid with an unprecedented 5/5/7/6 ring system. A pair of enantiomers, (±)-glaucatotone B (2a/2b), represent the first rearranged norsesquiterpenoid with a (cyclopentylmethyl)cyclohexane skeleton. 3 is defined as a dinorsesquiterpenoid possessing a 5/7/5 ring system. 4-6 are three guaiane-type norsesquiterpenoids. In vitro bioactivity, 2a selectively inhibited Bcap-37 with IC

Identifiants

pubmed: 38281383
pii: S0045-2068(24)00040-3
doi: 10.1016/j.bioorg.2024.107135
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107135

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Xinyuan Pan (X)

School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311403, China.

Jiayi Cai (J)

The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310003, China.

Kaohua Liu (K)

School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311403, China.

Jiaqi Guo (J)

School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311403, China.

Siqi Li (S)

School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311403, China.

Ling Wang (L)

School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311403, China.

Lizhu Han (L)

School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311403, China.

Kexin Zhou (K)

School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311403, China.

Xiongyu Meng (X)

School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311403, China. Electronic address: mengxiongyu@zcmu.edu.cn.

Luping Qin (L)

School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311403, China. Electronic address: lpqin@zcmu.edu.cn.

Huaqiang Li (H)

School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311403, China. Electronic address: lihq009@zcmu.edu.cn.

Classifications MeSH